Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • New drug therapy approvals in 2017

    by
    • Optum Workers' Comp
    | Feb 01, 2018
    Tag Icon
    The U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has published their annual report, Advancing Health through Innovation: New Drug Approvals and Other Drug Therapy Advances of 2017. This report not only summarizes the approval of 46 new medications in 2017, it also provides information on the CDER’s role in supporting the FDA’s efforts to endorse innovation, efficiently execute the review and approval of new medications while maintaining patient safety, and improve various treatments for patients


  • Using the forest to see the trees

    by
    • Optum Workers' Comp
    | Dec 08, 2016
    Tag Icon
    Workers' Compensation
    A claimant’s pharmacy and demographic factors such as the body part and nature of injury, and their vital statistics (for example, gender, age and geography), provide us with significant insight into a claim. Important insight is also gained from understanding their pharmacy behavior; such as the types of medications being used, how often their prescriptions are refilled and how many pharmacies are used to fill their prescriptions. Yet another source of invaluable information is the prescriber.


  • Helios Analysis Identifies Decline in Utilization of Opioid Analgesics among Trends Influencing Pharmacy Claim Outcomes

    by
    • Helios
    | Apr 02, 2015
    Tag Icon
    We've released our 2015 Workers' Compensation Drug Trends report! The comprehensive report provides an inside look at the trends affecting your business, including the key drivers of pharmacy spend.






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.